The DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Open accessAbstract
BACKGROUND Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (FOLFOXIRI; fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab seem able to increase the immunogenicity of pMMR or MSS tumours. We aimed to provide preliminary evidence of benefit from the addition of the anti-PD-L1 agent atezolizumab to first-line FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer. METHODS AtezoTRIBE was a multicentre, open-label, randomised, controlled, phase 2 study of patients (aged 18-70 years with an Eastern Cooperative Oncology Group [ECOG] performance status of 0-2 and aged 71-75 years with an ECOG performance status of 0) with histologically confirmed, unresectable, previously untreated metastatic colorectal cancer and adequate organ function, who were recruited from 22 oncology centres in Italy. Patients were stratified according to centre, ECOG performance status, primary tumour site, and previous adjuvant therapy. A randomisation system incorporating a minimisation algorithm randomly assigned (1:2) patients via a masked web-based allocation procedure to two groups: the control group received first-line FOLFOXIRI (intravenous 165 mg/m2 irinotecan, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin, and 3200 mg/m2 fluorouracil as a 48 h infusion) plus bevacizum…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with a roughly 30% decreased hazard ratio of death (HR = 0.69; p = 0.012)”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [82]
In the citing paper
“The atezolizumab group had a 13.1-month progression-free survival versus 11.5 months in the control group”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [82]
In the citing paper
“A modification of the IS, termed “Immunoscore-Immune Checkpoint” (IS-IC), a systematic analysis of the density and vicinity of PD-L1 positive tumour cells and CD8+ T cells, prognostically stratifies patients with mCRC treated with the combination of FOLFOXIRI, bevacizumab and with or without anti-PD-L1 antibody atezolizumab.”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [110]
In the citing paper
“In the AtezoTRIBE study, a high IS-IC before initiation of treatment was associated with superior survival in the atezolizumab-treated pMMR/MSS mCRC subgroup.110”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [110]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Research works printed but not linked: 1
- Lee, 2018, Proc Am Soc Clin Oncol, 36
Cited by
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 669
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Invasion and metastasis in cancer: molecular insights and therapeutic targets
Li, Y., Liu, F., Cai, Q., Deng, L., Ouyang, Q., Zhang, X. H.-F., & Zheng, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02148-4 · Cited by 244
Chen, Y., Jia, K., Sun, Y., Zhang, C., Li, Y., Zhang, L., Chen, Z., Zhang, J., Hu, Y., Yuan, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32570-z · Cited by 206
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citation
Metadata
- Authors
- Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., Ambrosini, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Kassambara, A., Sbarrato, T., Morano, F., Ritorto, G., Borelli, B., Boccaccino, A., Conca, V., Giordano, M., Ugolini, C., Fieschi, J., Papadopulos, A., Massoué, C., Aprile, G., Antonuzzo, L., Gelsomino, F., Martinelli, E., Pella, N., Masi, G., Fontanini, G., Boni, L., Galon, J., & Cremolini, C.
- Affiliations
- University of Pisa (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Università Cattolica del Sacro Cuore (IT)
- Istituto Oncologico Veneto (IT)
- Ospedale "Santa Maria delle Croci" di Ravenna (IT)
- Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card. G. Panico" (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Ospedale San Bortolo (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Azienda sanitaria universitaria Friuli Centrale (IT)
- Ospedale Policlinico San Martino (IT)
- Inserm (FR)
- Corresponding author
- Cremolini, Chiara
- ORCID
- Antoniotti, Carlotta
- Rossini, Daniele
- Pietrantonio, Filippo
- Catteau, Aurélie
- Salvatore, Lisa
- Lonardi, Sara
- Boquet, Isabelle
- Tamberi, Stefano
- Marmorino, Federica
- Moretto, Roberto
- Ambrosini, Margherita
- Tamburini, Emiliano
- Tortora, Giampaolo
- Passardi, Alessandro
- Bergamo, Francesca
- Kassambara, Alboukadel
- Sbarrato, Thomas
- Morano, Federica
- Borelli, Beatrice
- Boccaccino, Alessandra
- Conca, Veronica
- Giordano, Mirella
- Ugolini, Clara
- Fieschi, Jacques
- Aprile, Giuseppe
- Antonuzzo, Lorenzo
- Gelsomino, Fabio
- Martinelli, Erika
- Masi, Gianluca
- Fontanini, Gabriella
- Boni, Luca
- Galon, Jérôme
- Cremolini, Chiara
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 23
- Issue
- 7
- Pages
- 876-887
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4281627748
- Cited by
- 280
- References
- 36
- Citations by year
- 2026: 50 · 2025: 69 · 2024: 89 · 2023: 58 · 2022: 14
- FWCI
- 24.05
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
- Florence Research (University of Florence) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- metastatic colorectal cancer, FOLFOXIRI, bevacizumab, atezolizumab, PD-L1 blockade, immune checkpoint inhibitors, first-line therapy, proficient mismatch repair, immunogenicity, progression-free survival, maintenance therapy, irinotecan, oxaliplatin
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Colonic Neoplasms, Fluorouracil, Humans, Organoplatinum Compounds, Rectal Neoplasms, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00274-1
- The paper
- Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., Ambrosini, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Kassambara, A., Sbarrato, T., Morano, F., Ritorto, G., . . . Cremolini, C. (2022). Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00274-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.